Cinnarizine and Mexidol Compatibility

• Nootropic agent [Nootropics].

The content of the article:
  1. Nosology
  2. Prepart Components
  3. Description of dosage form
  4. pharmachologic effect
  5. Pharmacodynamics
  6. Pharmacokinetics
  7. Indications for use
  8. contraindications
  9. Application in pregnancy and lactation
  10. S >Incidence of side effects. Very rare (. If any of the side effects indicated in the instructions are exacerbated, or any other side effects not listed in the instructions have been noticed, you should inform your doctor.
  11. Interaction
  12. Dosing and Administration
  13. Overdose
  14. special instructions
  15. Conditions of leave from pharmacies
  16. Storage conditions
  17. Shelf life
  18. Contraindications
  19. Contraindications Citicoline.
  20. S >Side effects are grouped by frequency of occurrence: very often (≥1/10); often (≥1/100 to. Very rarely, including individual cases. Allergic reactions. Rash, pruritus, anaphylactic shock. From the central nervous system and peripheral nervous system. Insomnia, headache, dizziness, tremors, numbness in paralyzed limbs, stimulation of the parasympathetic nervous system. From the psyche. Hallucinations, agitation. From the CCC. Short-term change in blood pressure. From the digestive system. Nausea, vomiting, diarrhea, decreased appetite, changes in the activity of liver enzymes. Other. Feeling of heat, swelling, shortness of breath.
  21. Firms manufacturers (or distributors) of the drug
  22. Titles
  23. Farm Group
  24. Prepart Components
  25. Description of dosage form
  26. pharmachologic effect
  27. Pharmacodynamics
  28. Pharmacokinetics
  29. Indications for use
  30. contraindications
  31. Application in pregnancy and lactation
  32. S >Very rarely (. Allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, loss of appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes In some cases, the drug Rekognan can stimulate the parasympathetic system, as well as have a short-term effect on blood pressure. If any of the side effects listed in the description are exacerbated or any other side effects not listed in the description appear, you should inform your doctor.
  33. Dosing and Administration
  34. special instructions
  35. Storage conditions
  36. Shelf life
  37. Firms manufacturers (or distributors) of the drug
  38. Titles
  39. Prepart Components
  40. Description of dosage form
  41. Pharmacodynamics
  42. Pharmacokinetics
  43. contraindications
  44. Application in pregnancy and lactation
  45. S >Side effects are grouped by frequency of occurrence: very often (≥1/10); often (≥1/100 to. Very rarely (including individual cases) – allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, a change in the activity of liver enzymes. In some cases, citicoline can stimulate the parasympathetic system, as well as provide a short-term change in blood pressure. If any of the side effects listed in the description are exacerbated or the patient has noticed other side effects not listed in the description, you should inform your doctor.
  46. Interaction
  47. Dosing and Administration
  48. special instructions
  49. Storage conditions
  50. Shelf life
  51. Firms manufacturers (or distributors) of the drug
  52. Side effects of the components
  53. How to take Mexidol and Cinnarizine
  54. pharmachologic effect
  55. contraindications
  56. Contraindications
  57. What is better and what is the difference between Mexidol and Cinnarizine
  58. Description of dosage form
  59. Side effects of the components
  60. Opinion of doctors
  61. Patient Reviews
  62. Mexidol increases or decreases blood pressure?
  63. Composition
  64. Mechanism of action
  65. Forms of release
  66. contraindications
  67. Side effects
  68. Reviews
  69. Application in pregnancy and lactation
  70. Dosing and Administration
  71. special instructions

more - Cinnarizine and Mexidol CompatibilityNosology

(Data taken from Citicoline active ingredient).
• F06,7 Mild cognitive impairment.
• F91 Behavioral Disorders.
• I63 cerebral infarction.
• I67,9 Cerebrovascular disease, unspecified.
• I69,1 Consequences of intracranial hemorrhage.
• I69,3 Consequences of cerebral infarction.
• S06 Intracranial injury.
• T90,5 Consequences of intracranial injury.

Prepart Components

Solution for intravenous and intramuscular administration4 ml
active substance:
citicoline sodium522,5 mg
(equivalent to 500 mg citicoline)
citicoline sodium1045 mg
(equivalent to 1000 mg citicoline)
excipients: 1M hydrochloric acid or 1M sodium hydroxide – up to pH 6,7–7,1; water for injection – up to 4 ml
Solution for oral administration1 ml
active substance:
citicoline sodium104,5 mg
(equivalent to 100 mg citicoline)
excipients: sorbitol – 200 mg; glycerol – 50 mg; methyl parahydroxybenzoate – 1,45 mg; propyl parahydroxybenzoate – 0,25 mg; sodium citrate dihydrate – 6 mg; sodium saccharinate – 0,2 mg; strawberry flavor (strawberry essence 1487-S-Lucta) – 0,408 mg; potassium sorbate – 3 mg; citric acid 50% solution – up to pH 6; purified water – up to 1 ml
Solution for oral administration1 pack (10 ml)
active substance:
citicoline sodium1045 mg
(equivalent to 1000 mg citicoline)
excipients: sorbitol – 2000 mg; glycerol – 500 mg; methyl parahydroxybenzoate – 14,5 mg; propyl parahydroxybenzoate – 2,5 mg; sodium citrate dihydrate – 60 mg; sodium saccharinate – 2 mg; strawberry flavor (strawberry essence 1487-S-Lucta) – 4,08 mg; potassium sorbate – 30 mg; citric acid 50% solution – up to pH 6; purified water – up to 10 ml

Description of dosage form

Solution for intravenous and intramuscular administration. Transparent colorless liquid.
Solution for oral administration. Transparent colorless liquid with a characteristic strawberry odor.
Solution for intravenous and intramuscular administration, 500 mg/4 ml and 1000 mg/4 ml: in ampoules of colorless neutral glass (hydrolytic type I) with protective plastic tubes and white stripes for breaking ampoules, 4 ml each; in blister packs of PVC 3 or 5 amp. ; in a pack of cardboard 1 package of 3 or 5 amp. Or 2 packs of 5 amp.
Solution for oral administration, 100 mg/ml. 30 ml of the drug in a bottle of colorless transparent glass, sealed with a screw-on plastic cover, providing control of the first opening. The vial, together with a dosing syringe, is placed in a cardboard bundle having a septum inside.
Solution for oral administration, 100 mg/ml. 10 ml of the drug in a bag of combined material (polyethylene terephthalate/polystyrene/aluminum foil/Surlin polymer film). 6 or 10 sachets are placed in a cardboard box.

pharmachologic effect

The pharmacological action is nootropic.

Pharmacodynamics

Citicoline, being a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action – helps to restore damaged cell membranes, inhibits the action of phospholipases, prevents excessive formation of free radicals, and also prevents cell death by acting on the mechanisms of apoptosis. In the acute period of a stroke, citicoline reduces the amount of damage to brain tissue, improves cholinergic transmission. When TBI reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, reduces the duration of the recovery period.
In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive disorders, such as memory impairment, lack of initiative, difficulties encountered in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.
Citicoline is effective in treating sensory and motor neurological disorders of degenerative and vascular etiology.

Pharmacokinetics

Suction. Citicoline is well absorbed with intravenous and intramuscular administration. Absorption after oral administration is almost complete, and the bioavailability is almost the same as after intravenous administration.
Metabolism. With iv and intramuscular administration, citicoline is metabolized in the liver with the formation of choline and cytidine. After administration, plasma choline concentrations increase significantly.
Distribution. Citicoline is largely distributed in brain structures, with the rapid incorporation of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Citicoline penetrates the brain and actively integrates into cell, cytoplasmic and mitochondrial membranes, forming part of the fraction of structural phospholipids.
Breeding. Only 15% of the administered dose of citicoline is excreted from the human body; less than 3% – by the kidneys and about 12% – with exhaled CO2.
In urinary excretion of citicoline, 2 phases can be distinguished: the first phase, which lasts about 36 hours, during which the excretion rate decreases rapidly, and the second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled CO2 – the rate of excretion decreases rapidly after about 15 hours, and then decreases much more slowly.

Indications for use

The acute period of ischemic stroke (as part of complex therapy);
The recovery period of ischemic and hemorrhagic strokes;
TBI, acute (as part of complex therapy) and the recovery period;
Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

contraindications

Hypersensitivity to any of the components of the drug;
Severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
Rare hereditary diseases associated with fructose intolerance;
Children under 18 years of age (due to lack of sufficient clinical data).

Application in pregnancy and lactation

There are no sufficient data on the use of citicoline in pregnant women. Although animal studies have not revealed a negative effect, during pregnancy, the drug Cerakson is prescribed only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.
When prescribing Ceraxon during lactation, women should stop breastfeeding, since there is no data on the allocation of citicoline with breast milk.

S >Incidence of side effects.
Very rare (.
If any of the side effects indicated in the instructions are exacerbated, or any other side effects not listed in the instructions have been noticed, you should inform your doctor.

Interaction

Citicoline enhances the effects of levodopa.
It should not be administered simultaneously with drugs containing meclofenoxate.

Dosing and Administration

Solution for in/in, in/m introduction.
IV, in the form of a slow IV injection (for 3 – 5 min, depending on the prescribed dose) or drip IV injection (40 – 60 drops per minute).
In/in the route of administration is preferable to the/m. When i/m injection should be repeated administration of the drug in the same place.
Recommended dosage.
Acute period of ischemic stroke and head injury. 1000 mg every 12 hours from the first day after diagnosis, the duration of treatment is at least 6 weeks. 3-5 days after the start of treatment (if swallowing function is not impaired), the transition to oral forms of Ceraxon is possible.
The recovery period of ischemic and hemorrhagic strokes, the recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500–2000 mg per day. Dosage and duration of treatment – depending on the severity of the symptoms of the disease. Perhaps the use of oral forms of the drug Ceraxon.
Elderly patients.
When prescribing Ceraxon to older patients, dose adjustment is not required.
The solution in the ampoule is intended for single use. It should be used immediately after opening the ampoule.
The drug is compatible with all types of isotonic solutions and dextrose solutions.
Solution for oral administration.
Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 glass). Accepted with meals or between meals.
Recommended dosage.
Acute period of ischemic stroke and head injury. 1000 mg (10 ml or 1 pack.) Every 12 Duration of treatment for at least 6 weeks.
The recovery period of ischemic and hemorrhagic strokes, the recovery period of brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500–2000 mg per day (5–10 ml or 1 pack (1000 mg) 1-2 times a day). Dosage and duration of treatment – depending on the severity of the symptoms of the disease.
Elderly patients.
When prescribing Ceraxon to older patients, dose adjustment is not required.
Instructions for using the dosing syringe (1):
Figure 1.
1. Place the dosing syringe into the vial (the piston of the syringe is completely lowered) (1 (1).
2. Gently pull the plunger of the dosing syringe until the level of the solution equals the corresponding mark on the syringe (1 (2).
3. Before taking, the right amount of solution can be diluted in 1/2 cup of water (120 ml) (1 (3).
After each use, it is recommended to wash the dosing syringe with water.
Recommendations for the use of Ceraxon in sachets.
1. Separate one bag from the other along the tear-off seam. While holding the bag vertically, carefully tear off its edge at the “Open here” mark (2).
Figure 2.
2. The contents of the sachet can be drunk immediately after opening (3) or can be diluted in 1/2 cup of water (120 ml) (4) before administration.
Figure 3.
Figure 4.

Overdose

Given the low toxicity of the drug overdose cases are not described.

special instructions

During the treatment period, caution should be exercised when performing potentially hazardous activities that require special attention and quick reactions (driving and other vehicles, working with moving mechanisms, the work of the dispatcher and operator, etc.;).
Solution for oral administration (optional). A small amount of crystals may form in the cold due to the temporary partial crystallization of the preservative. Upon further storage under recommended conditions, the crystals dissolve within a few months. The presence of crystals does not affect the quality of the drug.

Conditions of leave from pharmacies

Storage conditions

At a temperature not exceeding 30 ° C. Keep out of the reach of children.

Shelf life

3 year.
Do not use after the expiry date printed on the package.

Contraindications

Detonic – a unique medicine that helps fight hypertension at all stages of its development.

Detonic for pressure normalization

The complex effect of plant components of the drug Detonic on the walls of blood vessels and the autonomic nervous system contribute to a rapid decrease in blood pressure. In addition, this drug prevents the development of atherosclerosis, thanks to the unique components that are involved in the synthesis of lecithin, an amino acid that regulates cholesterol metabolism and prevents the formation of atherosclerotic plaques.

Detonic not addictive and withdrawal syndrome, since all components of the product are natural.

Detailed information about Detonic is located on the manufacturer’s page www.detonicnd.com.

Contraindications Citicoline.

Hypersensitivity; patients with severe vagotonia (high tone of the parasympathetic part of the autonomic nervous system); children under 18 years of age (due to lack of sufficient clinical data).

S >Side effects are grouped by frequency of occurrence: very often (≥1/10); often (≥1/100 to.
Very rarely, including individual cases.
Allergic reactions. Rash, pruritus, anaphylactic shock.
From the central nervous system and peripheral nervous system. Insomnia, headache, dizziness, tremors, numbness in paralyzed limbs, stimulation of the parasympathetic nervous system.
From the psyche. Hallucinations, agitation.
From the CCC. Short-term change in blood pressure.
From the digestive system. Nausea, vomiting, diarrhea, decreased appetite, changes in the activity of liver enzymes.
Other. Feeling of heat, swelling, shortness of breath.

Firms manufacturers (or distributors) of the drug

Ferrer International SA 18973 - Cinnarizine and Mexidol CompatibilityRekognan

Titles

Russian name: Rekognan.
English name: Recognan.

Farm Group

• Nootropic agent [Other neurotropic drugs].

Prepart Components

Solution for oral administration1 ml
active substance:
citicoline monosodium salt1045 mg
(equivalent to 100 mg citicoline)
excipients: sorbitol – 200 mg; glycerol – 50 mg; methyl parahydroxybenzoate – 1,45 mg; propyl parahydroxybenzoate – 0,25 mg; potassium sorbate – 3 mg; sodium citrate dihydrate – 6 mg; sodium saccharinate – 0,2 mg; strawberry flavor FRESA S. 1487S – 0,4 mg; citric acid – up to pH 6; purified water – up to 1 ml

Description of dosage form

Transparent colorless liquid with a characteristic strawberry odor.
Solution for oral administration, 100 mg/ml.
Bottle. 30 ml of the drug in a clear glass bottle of hydrolytic class III, sealed with a white screw cap made of polypropylene with an inner lining made of LDPE and a first opening control or a white screw cap made of PE with a PE sealing element and a first opening control. A bottle with a dispensing pipette is placed in a pack of cardboard boxed.
Sachets. 10 ml of the drug in a bag of a multilayer composite material (PET-LDPE-aluminum-PE). 5 or 10 pack. Put in a pack of cardboard boxed.

pharmachologic effect

Pharmacological action – nootropic, neuroprotective.

Pharmacodynamics

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action – it helps to restore damaged cell membranes, inhibits the action of phospholipases, prevents excessive formation of free radicals, and also prevents cell death by acting on the mechanisms of apoptosis. In the acute period of a stroke, it reduces the volume of damage to brain tissue, improves cholinergic transmission. In TBI, the duration of post-traumatic coma and the severity of neurological symptoms are reduced, in addition, it helps to reduce the duration of the recovery period.
Citicoline is effective in the treatment of cognitive, sensitive and motor neurological disorders of degenerative and vascular etiology.
In chronic cerebral ischemia, citicoline is effective in the treatment of disorders such as memory impairment, lack of initiative, difficulties encountered in performing daily self-care activities. Increases the level of attention and consciousness, and also reduces the manifestations of amnesia.

Pharmacokinetics

Suction. Citicoline is well absorbed by ingestion. Absorption after oral administration is almost complete, and the bioavailability is approximately the same as after iv administration.
Metabolism. The drug is metabolized in the intestines and liver with the formation of choline and cytidine. After administration, the concentration of choline in the blood plasma increases significantly.
Distribution. Citicoline is largely distributed in brain structures, with the rapid incorporation of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Citicoline penetrates the brain and actively integrates into cell, cytoplasmic and mitochondrial membranes, forming part of the fraction of structural phospholipids.
Breeding. Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% – by the kidneys and through the intestines and about 12% – with exhaled air.
In urinary excretion of citicoline, 2 phases can be distinguished: the 1st phase, lasting about 36 hours, during which the excretion rate decreases rapidly, and the 2nd, during which the excretion rate decreases much more slowly. The same thing is observed in exhaled air – the rate of excretion decreases rapidly after about 15 hours, and then decreases much more slowly.

Indications for use

The acute period of ischemic stroke (as part of complex therapy);
The recovery period of ischemic and hemorrhagic strokes;
Craniocerebral trauma, acute (as part of complex therapy) and recovery periods;
Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

contraindications

Hypersensitivity to any of the components of the drug;
Severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
Rare hereditary diseases associated with fructose intolerance;
Children under 18 years of age (due to lack of sufficient clinical data).

Application in pregnancy and lactation

There are no sufficient data on the use of citicoline in pregnant women.
Although no negative effects have been found in animal studies, Rekognan is prescribed during pregnancy only when the expected benefit to the mother outweighs the potential risk to the fetus.
When prescribing Rekognan during lactation, women should stop breastfeeding, since there is no data on the release of citicoline with breast milk.

S >Very rarely (. Allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, loss of appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes In some cases, the drug Rekognan can stimulate the parasympathetic system, as well as have a short-term effect on blood pressure.
If any of the side effects listed in the description are exacerbated or any other side effects not listed in the description appear, you should inform your doctor.

Dosing and Administration

Inside, with meals or between meals. Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup).
Doses are calculated based on the content of citicoline in 1 ml (100 mg), in 1 pack. (10 ml) contains 1000 mg of citicoline; in 1 fl. (30 ml) – 3000 mg.
Recommended dosage.
Acute period of ischemic stroke and head injury. 1000 mg (10 ml) every 12 Duration of treatment for at least 6 weeks.
The recovery period of ischemic and hemorrhagic strokes, head injury; cognitive and behavioral disorders in degenerative and vascular diseases of the brain. 500–2000 mg (5–20 ml) per day. Dosage and duration of treatment depend on the severity of the symptoms of the disease.
Special patient groups.
Elderly age. When prescribing Rekognan to elderly patients, dose adjustment is not required.
Instructions for use of the drug Rekognan in bottles using the pipette pipette attached to it.
1. Place the pipette into the vial (the pipette piston is completely lowered).
2. Gently pull the metering pipette by the piston until the solution level is equal to the corresponding mark on the pipette.
3. Before taking, the required amount of solution can be diluted in 1/2 glasses of water (120 ml).
After each use, it is recommended to flush the pipette with a dosing water.
Recommendations for the use of the drug Rekognan in bags.
1. Take a bag of Rekognan over the edge and shake.
2. Tear off the edge of the bag at the dotted line.
3. Drink the contents of the bag immediately after opening or dissolve in 1/2 cups of drinking water (120 ml) and drink.

!  Why does diabetes hurt legs and what to do about it

special instructions

In the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative. Upon further storage under recommended conditions, the crystals dissolve within a few months. The presence of crystals does not affect the quality of the drug.
Influence on the ability to drive vehicles, mechanisms. During the treatment period, care must be taken when performing potentially hazardous activities that require increased attention and speed of psychomotor reactions (including driving a car and other vehicles, working with moving mechanisms, the work of a dispatcher, operator).

Storage conditions

At a temperature of 15–25 ° C. Keep out of the reach of children.

Shelf life

A solution for oral administration of 100 mg/ml – 2 years.
Do not use after the expiry date printed on the package.

Firms manufacturers (or distributors) of the drug

Alfa Wassermann, Farmasierra Manufacturing SL, Alfasigma S.p.A. , GEROPHARM, Moscow pharmaceutical factory, Moscow endocrine factory FSUE, SAG Manufacturing S.L.U. 15304 - Cinnarizine and Mexidol CompatibilityNapilept

Titles

Name of the drug: Neupilept.

Prepart Components

Solution for intravenous and intramuscular administration1 amp.
active substance:
sodium citicoline (in terms of citicoline)500/1000 mg
excipients: 1 M solution of hydrochloric acid or 1 M solution of sodium hydroxide to a pH of 6,5-7,5; water for injection – up to 4 ml

Description of dosage form

Transparent colorless liquid.
Solution for intravenous and intramuscular administration, 125 mg/ml and 250 mg/ml. 4 ml in ampoules of colorless glass with a colored fracture ring or with a colored dot and a notch. The ampoules are additionally coated with 1, 2 or 3 color rings and/or a two-dimensional barcode, and/or an alphanumeric coding, or without additional color rings, a two-dimensional barcode, and an alphanumeric coding.
3 or 5 amp. In blister packs made of PVC film and aluminum foil or polymer film or without foil and without film.
1 blister strip packaging of 3 or 5 amp. Put in a pack of cardboard.
2 blister packs of 5 amp each. Put in a pack of cardboard.

Pharmacodynamics

Citicoline is a natural endogenous compound that is an intermediate metabolite in the synthesis of phosphatidylcholine, one of the main structural components of the cell membrane.
It has a wide spectrum of action – it helps to restore damaged cell membranes, inhibits the action of phospholipases, prevents the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis. In the acute period of a stroke, citicoline reduces the amount of damage to brain tissue, improves cholinergic transmission. In TBI, the duration of post-traumatic coma and the severity of neurological symptoms are reduced, in addition, it helps to reduce the duration of the recovery period.
In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive disorders, such as memory impairment, lack of initiative, difficulties encountered in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.
Citicoline is effective in treating sensory and motor neurological disorders of degenerative and vascular etiology.

Pharmacokinetics

Metabolism. After iv administration, citicoline is rapidly hydrolyzed to choline and cytidine and delivered to various tissues of the body.
Distribution. After administration, citicoline is widely distributed in the brain structures with the rapid incorporation of the choline fraction into structural phospholipids and the cytidine fraction into cytidine nucleotides and nucleic acids. Having reached the brain, citicoline integrates into cell, cytoplasmic and mitochondrial membranes, taking part in the construction of the phospholipid fraction.
Breeding. Only a small amount of the dose is excreted by the kidneys and through the intestines (.

contraindications

Hypersensitivity to any of the components of the drug;
Patients with severe vagotonia (high tone of the parasympathetic part of the autonomic nervous system);
Children under 18 years of age (due to lack of sufficient clinical data).

Application in pregnancy and lactation

There are insufficient data on the use of citicoline in pregnant women. Although no negative effects have been found in animal studies, citicoline is prescribed during pregnancy only when the expected benefits to the mother outweigh the potential risk to the fetus.
When using citicoline during lactation, women should stop breastfeeding, since there is no data on the excretion of citicoline with breast milk.

S >Side effects are grouped by frequency of occurrence: very often (≥1/10); often (≥1/100 to.
Very rarely (including individual cases) – allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, a change in the activity of liver enzymes. In some cases, citicoline can stimulate the parasympathetic system, as well as provide a short-term change in blood pressure. If any of the side effects listed in the description are exacerbated or the patient has noticed other side effects not listed in the description, you should inform your doctor.

Interaction

Citicoline enhances the effects of levodopa.

Dosing and Administration

In/m, in/in, jet (slowly, for 3-5 minutes, depending on the prescribed dose) or drip (infusion rate – 40-60 drops/min).
In/in the route of administration is preferable to the/m. When i/m injection should be repeated administration of the drug in the same place.
The drug should be used immediately after opening the ampoule.
Recommended dosage.
Acute period of ischemic stroke and head injury. 1000 mg of citicoline every 12 hours from the first day after diagnosis, the duration of treatment is at least 6 weeks. The maximum daily dose is 2000 mg.
The recovery period of ischemic and hemorrhagic strokes, the recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500–2000 mg of citicoline per day in/in or/m. Dosage and duration of treatment – depending on the severity of the symptoms of the disease.
Elderly patients. When prescribing Neupilept to elderly patients, dose adjustment is not required.
NEIPILEPT is compatible with all types of iv in isotonic solutions and dextrose solutions.

special instructions

In/in a jet NEIPILEPT is entered slowly (3-5 minutes, depending on a dose). With iv drip, the infusion rate should be 40-60 drops/min.
With persistent intracranial hemorrhage, it is recommended not to exceed the dose of NEIPILEPT 1000 mg/day, the drug is administered intravenously at a rate of 30 drops/min.
Influence on the ability to drive vehicles, mechanisms. During the use of the drug, caution should be exercised when driving and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

Storage conditions

At a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life

2 year.
Do not use after the expiry date printed on the package.

Firms manufacturers (or distributors) of the drug

Side effects of the components

Incidence of side effects. Very rare (. If any of the side effects indicated in the instructions are aggravated, or any other side effects not listed in the instructions have been noticed, you should inform your doctor.

Side effects are grouped by frequency of occurrence: very often (≥1/10); often (≥1/100 to. Rash, pruritus, anaphylactic shock. Insomnia, headache, dizziness, tremors, numbness in the paralyzed limbs, stimulation of the parasympathetic nervous system. Hallucinations, agitation. Short-term change in blood pressure. Nausea, vomiting, diarrhea, decreased appetite, changes in the activity of liver enzymes.Sense of heat, swelling, shortness of breath.

Very rarely (. Allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, loss of appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes In some cases, the drug Rekognan can stimulate the parasympathetic system, as well as have a short-term effect on blood pressure.

Side effects are grouped by frequency of occurrence: very often (≥1/10); often (≥1/100 to. Very rarely (including individual cases) – allergic reactions (rash, skin itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes.

Medications work well together. Simultaneous administration enhances the therapeutic effect of both drugs.

How to take Mexidol and Cinnarizine

Mexidol is available in tablet and liquid form. Injections are given intramuscularly or intravenously in the form of infusions. The maximum daily dosage is 1200 mg per day.

If tablets are prescribed, then the patient is shown 370-750 mg per day. Multiplicity of use – three times a day. In complicated cases, the dose is increased to 800 mg per day. The course of treatment lasts from 5 to 15 days.

Cinnarizine is available only in tablets. The average dosage is 25-50 mg 3 times a day. You can not take more than 200 mg per day, otherwise an overdose develops.

pharmachologic effect

• Nootropic agent [Nootropics].

The pharmacological action is nootropic.

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action – it helps to restore damaged cell membranes, inhibits the action of phospholipases, prevents excessive formation of free radicals, and also prevents cell death by acting on the mechanisms of apoptosis.

5a44afee64bb6537b1fab9b1591194d2 - Cinnarizine and Mexidol Compatibility

In the acute period of a stroke, citicoline reduces the amount of damage to brain tissue, improves cholinergic transmission. In TBI, the duration of post-traumatic coma and the severity of neurological symptoms are reduced, in addition, it helps to reduce the duration of the recovery period. In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive impairment, such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care.

Suction. Citicoline is well absorbed with intravenous and intramuscular administration. Absorption after oral administration is almost complete, and the bioavailability is almost the same as after intravenous administration. Metabolism. With iv and intramuscular administration, citicoline is metabolized in the liver with the formation of choline and cytidine. After administration, plasma choline concentrations increase significantly.

Distribution. Citicoline is largely distributed in brain structures, with the rapid incorporation of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Citicoline penetrates the brain and actively integrates into cell, cytoplasmic and mitochondrial membranes, forming part of the fraction of structural phospholipids. Breeding.

Only 15% of the administered dose of citicoline is excreted from the human body; less than 3% – by the kidneys and about 12% – with exhaled CO2. In urinary excretion of citicoline, 2 phases can be distinguished: the first phase, which lasts about 36 hours, during which the excretion rate decreases rapidly, and the second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled CO2 – the rate of excretion decreases rapidly after about 15 hours, and then decreases much more slowly.

• Nootropic agent [Other neurotropic drugs].

Pharmacological action – nootropic, neuroprotective.

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action – it helps to restore damaged cell membranes, inhibits the action of phospholipases, prevents excessive formation of free radicals, and also prevents cell death by acting on the mechanisms of apoptosis.

In the acute period of a stroke, it reduces the volume of damage to brain tissue, improves cholinergic transmission. In TBI, the duration of post-traumatic coma and the severity of neurological symptoms are reduced, in addition, it helps to reduce the duration of the recovery period. Citicoline is effective in the treatment of cognitive, sensitive and motor neurological disorders of degenerative and vascular etiology.

Suction. Citicoline is well absorbed by ingestion. Absorption after oral administration is almost complete, and the bioavailability is approximately the same as after iv administration. Metabolism. The drug is metabolized in the intestines and liver with the formation of choline and cytidine. After administration, the concentration of choline in the blood plasma increases significantly.

Distribution. Citicoline is largely distributed in brain structures, with the rapid incorporation of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Citicoline penetrates the brain and actively integrates into cell, cytoplasmic and mitochondrial membranes, forming part of the fraction of structural phospholipids. Breeding.

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% – by the kidneys and through the intestines and about 12% – with exhaled air. In urinary excretion of citicoline, 2 phases can be distinguished: the 1st phase, lasting about 36 hours, during which the excretion rate decreases rapidly, and the 2nd, during which the excretion rate decreases much more slowly. The same thing is observed in exhaled air – the rate of excretion decreases rapidly after about 15 hours, and then decreases much more slowly.

Citicoline is a natural endogenous compound that is an intermediate metabolite in the synthesis of phosphatidylcholine, one of the main structural components of the cell membrane. It has a wide spectrum of action – it contributes to the restoration of damaged cell membranes, inhibits the action of phospholipases, prevents the excessive formation of free radicals, and also prevents cell death by acting on the mechanisms of apoptosis.

In the acute period of a stroke, citicoline reduces the amount of damage to brain tissue, improves cholinergic transmission. In TBI, the duration of post-traumatic coma and the severity of neurological symptoms are reduced, in addition, it helps to reduce the duration of the recovery period. In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive impairment, such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care.

Metabolism. After iv administration, citicoline is rapidly hydrolyzed to choline and cytidine and delivered to various tissues of the body. Distribution. After administration, citicoline is widely distributed in the brain structures with the rapid incorporation of the choline fraction into structural phospholipids and the cytidine fraction into cytidine nucleotides and nucleic acids.

contraindications

Hypersensitivity to any of the components of the drug; Severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system); Rare hereditary diseases associated with fructose intolerance; Children under 18 years of age (due to lack of sufficient clinical data).

Hypersensitivity; patients with severe vagotonia (high tone of the parasympathetic part of the autonomic nervous system); children under 18 years of age (due to lack of sufficient clinical data).

Hypersensitivity to any of the components of the drug; Patients with severe vagotonia (high tone of the parasympathetic part of the autonomic nervous system); Children under 18 years of age (due to lack of sufficient clinical data).

The instructions for use with Mexidol indicate that the drug is prohibited for use with:

  • increased susceptibility to the components of the drug;
  • acute liver failure;
  • acute renal failure.

Cinnarizine is contraindicated for use at the stage of gestation and lactation, children under 12 years of age. With caution, the medicine is prescribed to patients with Parkinson’s disease.

Contraindications

Solution for intravenous and intramuscular administration4 ml
active substance:
citicoline sodium522,5 mg
(equivalent to 500 mg citicoline)
citicoline sodium1045 mg
(equivalent to 1000 mg citicoline)
excipients: 1M hydrochloric acid or 1M sodium hydroxide – up to pH 6,7–7,1; water for injection – up to 4 ml
Solution for oral administration1 ml
active substance:
citicoline sodium104,5 mg
(equivalent to 100 mg citicoline)
excipients: sorbitol – 200 mg; glycerol – 50 mg; methyl parahydroxybenzoate – 1,45 mg; propyl parahydroxybenzoate – 0,25 mg; sodium citrate dihydrate – 6 mg; sodium saccharinate – 0,2 mg; strawberry flavor (strawberry essence 1487-S-Lucta) – 0,408 mg; potassium sorbate – 3 mg; citric acid 50% solution – up to pH 6; purified water – up to 1 ml
Solution for oral administration1 pack (10 ml)
active substance:
citicoline sodium1045 mg
(equivalent to 1000 mg citicoline)
excipients: sorbitol – 2000 mg; glycerol – 500 mg; methyl parahydroxybenzoate – 14,5 mg; propyl parahydroxybenzoate – 2,5 mg; sodium citrate dihydrate – 60 mg; sodium saccharinate – 2 mg; strawberry flavor (strawberry essence 1487-S-Lucta) – 4,08 mg; potassium sorbate – 30 mg; citric acid 50% solution – up to pH 6; purified water – up to 10 ml
Solution for oral administration1 ml
active substance:
citicoline monosodium salt1045 mg
(equivalent to 100 mg citicoline)
excipients: sorbitol – 200 mg; glycerol – 50 mg; methyl parahydroxybenzoate – 1,45 mg; propyl parahydroxybenzoate – 0,25 mg; potassium sorbate – 3 mg; sodium citrate dihydrate – 6 mg; sodium saccharinate – 0,2 mg; strawberry flavor FRESA S. 1487S – 0,4 mg; citric acid – up to pH 6; purified water – up to 1 ml
Solution for intravenous and intramuscular administration1 amp.
active substance:
sodium citicoline (in terms of citicoline)500/1000 mg
excipients: 1 M solution of hydrochloric acid or 1 M solution of sodium hydroxide to a pH of 6,5-7,5; water for injection – up to 4 ml

What is better and what is the difference between Mexidol and Cinnarizine

Both drugs help improve cerebral circulation. But despite this, the drugs have differences.

!  Pressure 140 to 100 - what does it mean and is it dangerous

One of the main differences is the presence of an active ingredient and a therapeutic effect. The composition of Mexidol includes ethylmethylhydroxypyridine succinate. It is characterized by multifunctional action. It leads to a decrease in the formation of blood clots and the elimination of excess cholesterol.

The composition of the second medication includes cinnarizine. This component not only improves blood microcirculation in tissues, but also dilates blood vessels.

Description of dosage form

Solution for intravenous and intramuscular administration. Transparent colorless liquid. Solution for oral administration. Transparent colorless liquid with a characteristic strawberry odor. Solution for intravenous and intramuscular administration, 500 mg/4 ml and 1000 mg/4 ml: in ampoules of colorless neutral glass (hydrolytic type I) with protective plastic tubes and white stripes for breaking ampoules, 4 ml each;

in blister packs of PVC 3 or 5 amp. ; in a pack of cardboard 1 package of 3 or 5 amp. Or 2 packs of 5 amp. Solution for oral administration, 100 mg/ml. 30 ml of the drug in a bottle of colorless transparent glass, sealed with a screw-on plastic cover, providing control of the first opening.

The vial, together with a dosing syringe, is placed in a cardboard bundle having a septum inside. Solution for oral administration, 100 mg/ml. 10 ml of the drug in a bag of combined material (polyethylene terephthalate/polystyrene/aluminum foil/Surlin polymer film). 6 or 10 sachets are placed in a cardboard box.

Transparent colorless liquid with a characteristic strawberry odor. Solution for oral administration, 100 mg/ml. Bottle. 30 ml of the drug in a clear glass bottle of hydrolytic class III, sealed with a white screw cap made of polypropylene with an inner lining made of LDPE and a first opening control or a white screw cap made of PE with a PE sealing element and a first opening control.

Transparent colorless liquid. Solution for intravenous and intramuscular administration, 125 mg/ml and 250 mg/ml. 4 ml in ampoules of colorless glass with a colored fracture ring or with a colored dot and a notch. The ampoules are additionally coated with 1, 2 or 3 color rings and/or a two-dimensional barcode, and/or an alphanumeric encoding, or without additional color rings, a two-dimensional barcode, and an alphanumeric encoding.

Side effects of the components

During the use of medications, the patient may develop side symptoms.

When taking Mexidol, there are:

  • nausea and vomiting;
  • dry mouth and thirst;
  • drowsiness;
  • allergic reactions.

cinarizin 5 500 300 - Cinnarizine and Mexidol Compatibility

After taking the pill, dyspeptic syndrome often develops, which is characterized by a painful feeling in the stomach, belching, nausea, heartburn, bloating, and stool. There is a sharp increase or decrease in pressure, emotional reactivity, distal hyperhidrosis.

Cinnarizine tablets can also lead to the development of side effects. This process is accompanied by:

  • fatigue, drowsiness, depressive disorder, tremor of the extremities;
  • cholestatic jaundice, dyspeptic disorder, dry mouth;
  • increased sweating, allergic reactions, drop in blood pressure.

Rarely, lichen planus is rarely found.

Opinion of doctors

This group of drugs is prescribed for patients with vegetative-vascular dystonia, dyscirculatory encephalopathy, osteochondrosis. This combination of drugs leads to a stable positive result. There is a decrease in the frequency of fainting, panic attacks. Unpleasant symptoms in the form of migraine, dizziness and tinnitus disappear.

Dmitry, 36 years old, neurologist, Khakassia

It is difficult to find any drugs to improve cerebral circulation. The region offers medicines, but with a high cost. The only drugs available are cinnarizine and mexidol. They have a low price. Moreover, they effectively cope with the problems that arose as a result of circulatory disorders in the brain.

Cinnarizine can lead to increased fatigue, drowsiness, depressive disorder, tremor of the extremities.

Patient Reviews

Tatyana, 29 years old, Penza

A few years ago, they diagnosed osteochondrosis. Cinnarizine and Mexidol were prescribed in tablets. But after the start of the course, heartburn, abdominal pain, and nausea appeared. The doctor decided that such a reaction arose on Mexidol and transferred to injections. A positive effect was observed after 32 days. Now every six months I go through a preventive course.

Irina, 32 years old, Sevastopol

My father had an ischemic stroke. He spoke poorly and could not walk. The doctor advised to put droppers with Mexidol, and drink Cinnarizine tablets inside. One month after the start of treatment, a positive trend was observed. Father began to speak better and move slowly. During the year, 4 courses were completed.

Mexidol increases or decreases blood pressure?

For many years unsuccessfully struggling with hypertension?

Head of the Institute: “You will be amazed how easy it is to cure hypertension by taking it every day.

Mexidol is a medication developed by domestic scientists. This medicine has entered the medical practice of therapists, narcologists, surgeons, neurologists and psychiatrists since 1996.

Composition

The main component is a substance, the name of which is succinate ethylmethylhydroxypyridine.

Mechanism of action

Using the drug, you can:

  • prevent the effect of free radicals on the body;
  • reduce the harm from a lack of oxygen, reflected in all systems and organs;
  • strengthen the memory mechanism;
  • increase learning
  • lower blood pressure (BP);
  • cure depression through the production of “hormones of joy”;
  • protect against intoxication at the cellular level;
  • remove the consequences of the syndrome that occurs when refusing alcohol;
  • get rid of cramps.

Forms of release

Available in several forms, among them:

  1. Tablets. They are intended for oral administration and have a mass of 125 g each. The package contains 10 pieces. (plate) or 90 pcs. (jar). The tablet has a white or cream color and a round shape. For special cases, for example, to lower or increase the pressure in the hospital, it is possible to purchase packages with a large quantity.
  2. Injections for injections. The substance contained in the ampoules is intended for intravenous and intramuscular administration. It has a yellow color or is completely transparent. Both are not deviations from the norm. The volume of one ampoule can be from 2 to 5 ml, the package usually contains 5 or 10 injections.

Prices for Mexidol vary depending on the manufacturer and the number of tablets (ampoules) in the package. On average, the price range is from 300 to 400 rubles. You can buy the drug only by prescription, there are no other options. Shelf life is 3 years. Keep in a place that is out of the reach of children. It should also be noted that it is rapidly excreted from the body.

This drug is prescribed if:

  • circulatory disorders;
  • toxic effects on the body;
  • inflammatory processes in the acute phase, the foci of which are in the abdominal cavity;
  • hypoxia;
  • neurosis, depression;
  • traumatic brain injuries;
  • atherosclerosis, glaucoma;
  • alcohol addiction;
  • cardiovascular diseases (vegetovascular dystonia, hypertension, acute myocardial infarction);
  • epileptic syndrome.

In general, it contributes to the cure of diseases due to the presence of antihypoxic, nootropic, membrane-protective, axiolytic and anticonvulsant actions.

For intramuscular or intravenous administration, injections and a dropper are used. The speed of the latter should not exceed 60 drops per minute. It is prepared by adding substances to physiological saline. The duration of the injection procedure is about 5 minutes.

For the treatment of hypertension, our readers have successfully used ReCardio. Seeing the popularity of this product, we decided to offer it to your attention. Read more here .

The number of procedures and dosage is determined by the doctor in accordance with the diagnosis. The end of the procedure should be accompanied by a gradual dose reduction and subsequent examination, which will ensure that there is no need to continue treatment.

The same applies to the administration of tablet forms. The minimum duration of such treatment is at least two weeks. An exception may be the removal of alcohol dependence, or rather, the consequences of stopping the use of alcoholic beverages. In this case, the medicine is used for a week.

The occurrence of an overdose can be triggered by the use of the drug in too large a volume, for example, with self-medication or an incorrect diagnosis. Such consequences can also occur when taking several types of drugs. For example, if you take medications of antidepressant groups or tranquilizers in parallel. The use of this medication will be an effective addition to the treatment of somatic diseases.

The medication is able to affect blood pressure. The answer to the question, “Mexidol” raises or lowers blood pressure, both options are true. With increased pressure, the so-called emotional explosion may become a likely consequence. Due to the similar effects of the patient who took this drug, it does not overcome sleep for a long time.

Mexidol lowers blood pressure? Can mexidol be taken at low pressure? Can Mexidol Affect Pressure? How to act with high blood pressure? Only a doctor can answer these and similar questions, since every reaction of the body is individual, that is, it depends on the physiological characteristics and lifestyle of each person.

The cause of problems with blood pressure in most cases is hypoxia. This condition can be briefly described as oxygen starvation. It provokes a narrowing of blood vessels and causes a general malaise. Another serious problem causing this pathology is bad habits, in particular, dependence on alcohol or drugs. The following actions of the medication allow you to increase or decrease pressure, depending on the situation:

  • direct effects on the brain, leading to improved metabolism;
  • protection against hypoxia and strengthening of blood vessels;
  • prevention of brain cell death from ischemic strokes.

contraindications

Compared with other options, the drug has a small number of contraindications, among which hypersensitivity to the main component and acute liver or kidney failure can be distinguished.

Side effects

Undesirable consequences when taking are:

  • sleeping condition;
  • allergic reactions;
  • digestion problems.

They occur infrequently, in principle, the tool is characterized by the rapid adoption of its body. The almost complete absence of side effects makes Mexidol convenient for use in pediatric pathologies. Moreover, it is suitable for both direct treatment and for prophylactic measures. Such portability is by no means characteristic of all analogues, which include:

  1. In tablet form, options such as:
  • Hypoxen;
  • “Glycine”;
  • Cerebronorm.
  1. In the form of injections:
  • “Vitagamma”;
  • Emoxibel
  • Cortexin.

This drug can be used in conjunction with other drugs that have a pronounced nootropic effect. This is acceptable to increase mental activity in children, in particular those who are diagnosed with “RRD”, as well as to return to the form of people who have had a coma or suffering from coronary heart disease.

The use of the drug together with Actovegin is most often used for problems with pressure. After all, blood pressure directly depends on the amount of oxygen in the body and on the adequacy of its intake. The state of hypoxia causes jumps in blood pressure, which leads to similar problems. The balance of the necessary element and the timely disposal of the spent composition can stabilize the condition and reduce the symptoms of hypertension and hypotension.

For the same purpose, “Cavinton” is used, in its composition the main component is the element, the source of which is a plant called the small periwinkle. Under its influence, blood vessels expand, blood flow in the brain area normalizes. A positive consequence of these processes is the prevention of excessive platelet aggregation and improved metabolism.

In addition to the options already listed, the following groups beneficially cooperate with it:

  • anticoagulants;
  • analgesics, narcotic and non-narcotic origin;
  • antiplatelet agents;
  • antiparkinsonian drugs;
  • antihypertensive drugs;
  • tranquilizers;
  • sugar products;
  • cytostatics;
  • diuretics.

The use of each combination must be approached with complete seriousness. Careful selection will ensure the rapid emergence of a positive effect.

The main difference is compatibility with alcohol. The drug allows you to protect the body from jumps Blood pressure and intoxication, which are manifestations of the influence of alcohol-containing substances. Unfortunately, it does not protect body cells from the damaging effects of addiction. Therefore, the drug partially removes the consequences of this dependence, but does not cure. Nevertheless, the drug is often used to eliminate cravings for alcohol.

Reviews

Most of the reviews are positive. Experts themselves note its great effectiveness. This universal medicine quickly relieves the symptoms of circulatory problems in both acute and chronic forms, helps with increased or decreased intracranial pressure, and affects the state of blood vessels throughout the body.

Moreover, patients and doctors mean both injections and tablets. That is, all produced forms have found their scope. Some categories of patients require regular monitoring during treatment. In particular, this applies to children. Since there were no special tests for them, they need to give medicine with extreme caution. In turn, during pregnancy and lactation it is strictly prohibited.

Application in pregnancy and lactation

There are no sufficient data on the use of citicoline in pregnant women. Although animal studies have not revealed a negative effect, during pregnancy, the drug Cerakson is prescribed only in cases where the expected benefit to the mother outweighs the potential risk to the fetus. When prescribing Ceraxon during lactation, women should stop breastfeeding, since there is no data on the allocation of citicoline with breast milk.

There are no sufficient data on the use of citicoline in pregnant women. Although no negative effects have been found in animal studies, Rekognan is prescribed during pregnancy only when the expected benefit to the mother outweighs the potential risk to the fetus. When prescribing Rekognan during lactation, women should stop breastfeeding, since there is no data on the release of citicoline with breast milk.

There are insufficient data on the use of citicoline in pregnant women. Although no negative effects have been found in animal studies, citicoline is prescribed during pregnancy only in cases where the expected benefits to the mother outweigh the potential risk to the fetus. When using citicoline during lactation, women should stop breastfeeding, since there is no data on the excretion of citicoline with breast milk.

Dosing and Administration

Solution for iv, intramuscular administration. In/in, in the form of a slow intravenous injection (within 3-5 minutes, depending on the prescribed dose) or drip in/in infusion (40-60 drops per minute). In/in the route of administration is preferred than in/m. With v/m administration, repeated administration of the drug at the same place should be avoided. Recommended dosage.

- Cinnarizine and Mexidol Compatibility

500-2000 mg per day. Dosage and duration of treatment – depending on the severity of the symptoms of the disease. Perhaps the use of oral forms of the drug Ceraxon. Elderly patients. When prescribing Ceraxon to older patients, dose adjustment is not required. The solution in the ampoule is intended for single use.

It should be used immediately after opening the ampoule. The drug is compatible with all types of iv in isotonic solutions and dextrose solutions. Solution for oral administration. Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup). It is taken with meals or between meals.

500–2000 mg per day (5–10 ml or 1 packet. (1000 mg) 1-2 times a day). Dosage and duration of treatment – depending on the severity of the symptoms of the disease. Elderly patients. When prescribing Ceraxon to older patients, dose adjustment is not required. Instructions for using the dosing syringe (1): Figure 1. 1.

Place the dosing syringe into the vial (the syringe plunger is completely lowered) (1 (1). 2. Gently pull the dosing syringe piston until the level of the solution is equal to the corresponding mark on the syringe (1 (2). 3. Before taking, the required amount of solution can be dilute in 1/2 cup of water (120 ml) (1 (3).

1e75e766a8878ce97e5822761bb7d243 - Cinnarizine and Mexidol Compatibility

After each use, it is recommended to flush the dosing syringe with water. Recommendations for the use of Ceraxon in sachets. 1. Separate one bag from the other along the tear-off seam. While holding the bag vertically, carefully tear off its edge at the “Open here” mark (2). Figure 2. 2. The contents of the sachet can be drunk immediately after opening (3) or, before administration, can be diluted in 1/2 cup of water (120 ml) (4). Figure 3. Figure 4.

Inside, with meals or between meals. Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup). Doses are calculated based on the content of citicoline in 1 ml (100 mg), in 1 pack. (10 ml) contains 1000 mg of citicoline; in 1 fl. (30 ml) – 3000 mg. Recommended dosage.

Acute period of ischemic stroke and head injury. 1000 mg (10 ml) every 12 Duration of treatment for at least 6 weeks. The recovery period of ischemic and hemorrhagic strokes, head injury; cognitive and behavioral disorders in degenerative and vascular diseases of the brain. 500–2000 mg (5–20 ml) per day.

Dosage and duration of treatment depend on the severity of the symptoms of the disease. Special patient groups. Elderly age. When prescribing Rekognan to elderly patients, dose adjustment is not required. Instructions for use of the drug Rekognan in bottles using the pipette pipette attached to it. 1.

Insert the pipette into the vial (the pipette piston is completely lowered). 2. Gently pull the metering pipette by the piston until the solution level is equal to the corresponding mark on the pipette. 3. Before taking, the right amount of solution can be diluted in 1/2 cup of water (120 ml). After each use, it is recommended to rinse the pipette with a dosing water.

In/m, in/in, jet (slowly, for 3-5 minutes, depending on the prescribed dose) or drip (infusion rate – 40-60 drops/min). In/in the route of administration is preferred than in/m. With v/m administration, repeated administration of the drug at the same place should be avoided. The drug should be used immediately after opening the ampoule.

500–2000 mg of citicoline per day in/in or/m. Dosage and duration of treatment – depending on the severity of the symptoms of the disease. Elderly patients. When prescribing Neupilept to elderly patients, dose adjustment is not required. NEIPILEPT is compatible with all types of iv in isotonic solutions and dextrose solutions.

special instructions

During the treatment period, caution should be exercised when performing potentially hazardous activities requiring special attention and quick reactions (driving a car and other vehicles, working with moving mechanisms, the work of a dispatcher and operator, etc.;). Solution for oral administration (optional).

A small amount of crystals may form in the cold due to the temporary partial crystallization of the preservative. Upon further storage under recommended conditions, the crystals dissolve within a few months. The presence of crystals does not affect the quality of the drug. Influence on the ability to drive vehicles, mechanisms.

In/in a jet NEIPILEPT is entered slowly (3-5 minutes, depending on a dose). With iv drip, the infusion rate should be 40-60 drops/min. With persistent intracranial hemorrhage, it is recommended not to exceed the dose of NEIPILEPT 1000 mg/day, the drug is administered intravenously at a rate of 30 drops/min.

Tatyana Jakowenko

Editor-in-chief of the Detonic online magazine, cardiologist Yakovenko-Plahotnaya Tatyana. Author of more than 950 scientific articles, including in foreign medical journals. He has been working as a cardiologist in a clinical hospital for over 12 years. He owns modern methods of diagnosis and treatment of cardiovascular diseases and implements them in his professional activities. For example, it uses methods of resuscitation of the heart, decoding of ECG, functional tests, cyclic ergometry and knows echocardiography very well.

For 10 years, she has been an active participant in numerous medical symposia and workshops for doctors - families, therapists and cardiologists. He has many publications on a healthy lifestyle, diagnosis and treatment of heart and vascular diseases.

He regularly monitors new publications of European and American cardiology journals, writes scientific articles, prepares reports at scientific conferences and participates in European cardiology congresses.

Detonic